Stifel Nicolaus Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)
at www.tipranks.com (Thu, 29-Oct 10:16 PM)
ORIC spotlights 84% confirmed ORR for enozertinib in 1L EGFR atypical NSCLC, with Phase 3 Redwood-1 planned for 1H 2027
Market Chameleon (Mon, 26-Oct 11:07 AM)
ORIC sets Oct. 23 call to spotlight enozertinib Phase 1b data for first-line NSCLC with EGFR atypical mutations
Market Chameleon (Tue, 20-Oct 11:08 AM)
